Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
Imaging outcomes for trials of remyelination in multiple sclerosis.
Laquinimod in multiple sclerosis.
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Treatment of neuromyelitis optica.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Multiple sclerosis: an immune or neurodegenerative disorder?
Analysis: Healthy babies born after accelerated elimination of teriflunomide
Immunomodulatory effects of Vitamin D in multiple sclerosis.
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)

Pages